About: Recent successes in therapeutics for Ebola virus disease: no time for complacency

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Recent successes in therapeutics for Ebola virus disease: no time for complacency Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Recent successes in therapeutics for Ebola virus disease: no time for complacency
Creator	Saunders, David Palacios, Gustavo Nasar, Farooq Sanchez-Lockhart, Mariano Kugelman, Jeffrey Crozier, Ian Mudhasani, Rajini Martin, S Chiang, Chih-Yuan Warren, Travis Iversen, Patrick Bixler, Sandra Eaton, Brett Kuhn, Jens Panchal, Rekha Pitt, Margaret Radoshitzky, Sheli Zumbrun, Elizabeth Cooper, Christopher Radoshitzky, S Shurtleff, Amy Cooper, C Palacios, G Duplantier, Allen Martins, Karen Phd, Zeng Sunay, Melek Zeng, Xiankun Chiang, C-Y Duplantier, Eaton Kane, C Kane, Christopher Kugelman, J Martin, Shannon Martins, K Meinig, J Meinig, Matthew Mhs, E Mudhasani, R Nasar, F Panchal, R Phd, Iversen Pitt, M Sanchez-Lockhart, M Saunders, D Shurtleff, A Sunay, A Warren, T Zumbrun,
Source	Elsevier; Medline; PMC
abstract	The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.
has issue date	2020-06-18(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(20)30282-6
bibo:pmid	32563280
has license	no-cc
sha1sum (hex)	0a976f770192ed0442e193e9abcbd3c12da95ece
schema:url	https://doi.org/10.1016/s1473-3099%2820%2930282-6
resource representing a document's title	Recent successes in therapeutics for Ebola virus disease: no time for complacency
has PubMed Central identifier	PMC7302789
has PubMed identifier	32563280
schema:publication	Lancet Infect Dis
resource representing a document's body	covid:0a976f770192ed0442e193e9abcbd3c12da95ece#body_text
is schema:about of	named entity 'Ebola virus disease' named entity 'survival' named entity 'MOLECULE' named entity 'VACCINES' named entity 'THEIR' named entity 'EBOLA VIRUS DISEASE' named entity 'VIRAL PERSISTENCE' named entity 'ADDED' named entity 'VALUE' named entity 'ANTIBODY' named entity 'SURVIVORS' named entity 'FILOVIRUS' named entity 'BUNDLED' named entity 'ONGOING' named entity 'THERAPEUTIC' named entity 'STATISTICALLY SIGNIFICANT' named entity 'improving' named entity 'The PALM' named entity 'monoclonal' named entity 'antivirals' named entity 'small-molecule' named entity 'antibody' named entity 'antivirals' named entity 'statistically significant' named entity 'Ebola virus disease' named entity 'virus disease' named entity 'Ebola' named entity 'breastmilk' named entity 'long-term' named entity 'small-molecule' named entity 'Ebola' named entity 'REGN-EB3' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software